Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa’s novel ovarian cancer vaccine technology.

Scroll to Top